TransCon CNP is an investigational prodrug ... unforeseen safety or efficacy results in Ascendis’ development programs or on-market products; unforeseen expenses related to commercialization ...
Under the terms of the alliance, Ascendis will carry out the early development of TransCon product candidates, funded by Novo Nordisk, with the pharma group taking over once they reach the ...
Er-Kim has extended its exclusive agreement with Ascendis Pharma, broadening the reach of three endocrinology treatments across multiple countries in Eurasia. This follows the initial exclusive ...
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes in its TransCon technologies to develop new therapies that address unmet ...
"In addition to once-weekly administration, these outcomes and a safety and tolerability profile comparable to placebo support TransCon CNP's potential to ... unforeseen safety or efficacy results in ...
TransCon CNP is an investigational prodrug of C-type natriuretic peptide (CNP) administered once weekly and designed to treat individuals with achondroplasia by providing continuous exposure of ...
COPENHAGEN, Denmark, March 31, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has submitted its New Drug Application (NDA) to the U.S. Food & Drug Administration ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback